Literature DB >> 20596731

A review and recommendations for optimal outcome measures of anxiety, depression and general distress in studies evaluating psychosocial interventions for English-speaking adults with heterogeneous cancer diagnoses.

Tim Luckett1, Phyllis N Butow, Madeleine T King, Mayumi Oguchi, Gaynor Heading, Nadine A Hackl, Nicole Rankin, Melanie A Price.   

Abstract

OBJECTIVE: The objective of this paper is to inform choice of optimal patient-reported outcome measures (PROMs) of anxiety, depression and general distress for studies evaluating psychosocial interventions for English-speaking adults with heterogenous cancer diagnoses.
METHODS: A systematic review was conducted to identify all PROMs used to assess anxiety, depression and general distress in randomised controlled trials (RCTs) of psychosocial interventions for people with cancer published between 1999 and May 2009. Candidate PROMs were evaluated for content, evidence of reliability and validity, clinical meaningfulness, comparison data, efficiency, ease of administration, cognitive burden and track record in identifying treatment effects in RCTs of psychosocial interventions. Property ratings were weighted and summed to give an overall score out of 100.
RESULTS: The Hospital Anxiety and Depression Scale (HADS) scored highest overall (weighted score = 77.5), followed by the unofficial short-form of the Profile of Mood States (POMS), the POMS-37 (weighted score = 60), and the Centre for Epidemiological Studies Depression Scale (CES-D) and original POMS (weighted score = 55 each).
CONCLUSIONS: The HADS' efficiency and substantial track record recommend its use where anxiety, mixed affective disorders or general distress are outcomes of interest. However, continuing controversy concerning the HADS depression scale cautions against dependence where depressive disorders are of primary interest. Where cost is a concern, the POMS-37 is recommended to measure anxiety or mixed affective disorders but does not offer a suitable index of general distress and, like the HADS, emphasises anhedonia in measuring depression. Where depression is the sole focus, the CES-D is recommended.

Entities:  

Mesh:

Year:  2010        PMID: 20596731     DOI: 10.1007/s00520-010-0932-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  124 in total

1.  A new psychosocial screening instrument for use with cancer patients.

Authors:  J Zabora; K BrintzenhofeSzoc; P Jacobsen; B Curbow; S Piantadosi; C Hooker; A Owens; L Derogatis
Journal:  Psychosomatics       Date:  2001 May-Jun       Impact factor: 2.386

2.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

3.  Rasch analysis of the dimensional structure of the Hospital Anxiety and Depression Scale.

Authors:  A B Smith; E P Wright; R Rush; D P Stark; G Velikova; P J Selby
Journal:  Psychooncology       Date:  2006-09       Impact factor: 3.894

Review 4.  Psychosocial interventions for patients with head and neck cancer: past, present, and future.

Authors:  Cherith J Semple; Kate Sullivan; Lynn Dunwoody; W George Kernohan
Journal:  Cancer Nurs       Date:  2004 Nov-Dec       Impact factor: 2.592

5.  Psychological and fitness changes associated with exercise participation among women with breast cancer.

Authors:  Bernardine M Pinto; Matthew M Clark; Nancy C Maruyama; Susan I Feder
Journal:  Psychooncology       Date:  2003-03       Impact factor: 3.894

6.  Development and pilot testing of a psychoeducational intervention for oral cancer patients.

Authors:  Mark R Katz; Jonathan C Irish; Gerald M Devins
Journal:  Psychooncology       Date:  2004-09       Impact factor: 3.894

7.  A brief POMS measure of distress for cancer patients.

Authors:  D F Cella; P B Jacobsen; E J Orav; J C Holland; P M Silberfarb; S Rafla
Journal:  J Chronic Dis       Date:  1987

8.  The value of the Hospital Anxiety and Depression Scale (HADS) for comparing women with early onset breast cancer with population-based reference women.

Authors:  R H Osborne; G R Elsworth; M A G Sprangers; F J Oort; J L Hopper
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

9.  Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions.

Authors:  Stephen J Lepore; Vicki S Helgeson; David T Eton; Richard Schulz
Journal:  Health Psychol       Date:  2003-09       Impact factor: 4.267

10.  Predicting psychological distress in patients with cancer: conceptual basis and reliability evaluation of a self-report questionnaire.

Authors:  M I Fitch; D Osoba; N Iscoe; J P Szalai
Journal:  Anticancer Res       Date:  1995 Jul-Aug       Impact factor: 2.480

View more
  49 in total

1.  Using Rasch analysis to examine the distress thermometer's cut-off scores among a mixed group of patients with cancer.

Authors:  Sylvie D Lambert; Julie F Pallant; Kerrie Clover; Benjamin Britton; Madeleine T King; Gregory Carter
Journal:  Qual Life Res       Date:  2014-04-01       Impact factor: 4.147

Review 2.  Quantifying psychological distress among cancer patients in interventions and scales: a systematic review.

Authors:  Mei-Ling Yeh; Yu-Chu Chung; Man-Ying F Hsu; Chin-Che Hsu
Journal:  Curr Pain Headache Rep       Date:  2014-03

3.  How does the Distress Thermometer compare to the Hospital Anxiety and Depression Scale for detecting possible cases of psychological morbidity among cancer survivors?

Authors:  Allison Boyes; Catherine D'Este; Mariko Carey; Christophe Lecathelinais; Afaf Girgis
Journal:  Support Care Cancer       Date:  2012-05-24       Impact factor: 3.603

4.  Audio recordings of mindfulness-based stress reduction training to improve cancer patients' mood and quality of life--a pilot feasibility study.

Authors:  Andrea Altschuler; Elana Rosenbaum; Peter Gordon; Sandra Canales; Andrew L Avins
Journal:  Support Care Cancer       Date:  2011-06-19       Impact factor: 3.603

5.  A pilot randomized controlled trial of brief cognitive-behavioral therapy for anxiety in patients with terminal cancer.

Authors:  Joseph A Greer; Lara Traeger; Heather Bemis; Jessica Solis; Ellen S Hendriksen; Elyse R Park; William F Pirl; Jennifer S Temel; Holly G Prigerson; Steven A Safren
Journal:  Oncologist       Date:  2012-06-11

6.  Anxiety and depression in the general population in Colombia: reference values of the Hospital Anxiety and Depression Scale (HADS).

Authors:  Andreas Hinz; Carolyn Finck; Yvonne Gómez; Isolde Daig; Heide Glaesmer; Susanne Singer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-06-08       Impact factor: 4.328

7.  Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome.

Authors:  Lesley Stafford; Fiona Judd; Penny Gibson; Angela Komiti; G Bruce Mann; Michael Quinn
Journal:  Support Care Cancer       Date:  2015-01-06       Impact factor: 3.603

8.  The effect of disgust-related side-effects on symptoms of depression and anxiety in people treated for cancer: a moderated mediation model.

Authors:  Philip A Powell; Haffiezhah A Azlan; Jane Simpson; Paul G Overton
Journal:  J Behav Med       Date:  2016-03-07

9.  Quality of life amongst lymphoma survivors in a developing country.

Authors:  Diana L C Ng; Y C Leong; Gin Gin Gan
Journal:  Support Care Cancer       Date:  2016-07-26       Impact factor: 3.603

10.  Longitudinal comparison of three depression measures in adult cancer patients.

Authors:  Shelley A Johns; Kurt Kroenke; Erin E Krebs; Dale E Theobald; Jingwei Wu; Wanzhu Tu
Journal:  J Pain Symptom Manage       Date:  2012-08-22       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.